易都科技旗下公司贏得臨床試驗場地管理項目

Research Alert: Azn Q1 2026 Beat As Oncology Remains Strong; Reaffirms 2026 Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:AstraZeneca (AZN) posted 13% total revenue growth (+8% at constant exchange rates, CER) to USD15.3B in Q1 2026, beating consensus estimates of USD14.9B, with oncology remaining the key contributor (+16% CER). Imfinzi climbed 30% CER, supported by multiple new launches, while Enhertu grew 34% CER on continued global demand, with core operating margin remaining broadly stable Y/Y at 35% despite R&D (+8% CER) and SG&A (+7% CER) expense increases. We continue to like AZN for its strong pipeline and numerous key data readouts throughout 2026, supported by four positive Phase 3 trials and 14 regulatory approvals achieved since Q4 2025. AZN reiterated its 2026 guidance for mid- to high-single-digit revenue growth and low double-digit core EPS growth, with currency movements expected to provide modest support. We see this compelling dataset helping support its ambitious target to reach USD80B in total revenue by 2030, with guidance that is more favorable than peers like Novartis.

Deutsche Bank's First-quarter Results Bolster EUR33 Billion Revenue Goal for 2026

Deutsche Bank (DBK.F) said Wednesday its robust first-quarter results provided the momentum required to achieve its full-year 2026 revenue target of 33 billion euros.For the three months ended March 31, profit attributable to shareholders rose 8% year over year to 2.12 billion euros, with EPS increasing 7% to 1.06 euros. Before tax, profit climbed 7% to 3.04 billion euros, while post-tax profit hit an all-time quarterly high of 2.17 billion euros, up 8% on an annual basis.Deutsche Bank's net revenue edged up to 8.67 billion euros from 8.52 billion euros a year ago on the back of strong performance across its strategic focus areas. The bank reported a 146 billion-euro year-on-year increase in assets under management to 1.8 trillion euros, aided by 22 billion euros in quarterly net inflows within its private bank and asset management businesses.The private bank and asset management segments also recorded net revenue growth of 5% and 10%, respectively, to 2.57 billion euros and 802 million euros. Meanwhile, the corporate bank unit saw a 7 billion-euro annual increase in loans, notably within trade finance, and the investment bank division achieved a 7% rise in fixed income and currencies financing revenues to 967 million euros, near the record prior year quarter."We delivered strong performance in the quarter, with [return on tangible equity] of 12.7% and cost/income ratio below 59%, through a high-quality earnings mix and durable growth... Our Investment Bank served as a valued advisor to clients in a challenging [macroeconomic] environment and our Corporate Bank's lending activity accelerated. This gives us a firm step-off point towards our financial targets and strategic objectives. We're building growth momentum in [high-value] businesses through targeted investments and deliberate capital allocation, and further cost flexibility through [artificial intelligence] and process reengineering across the bank," Deutsche Bank Chief Financial Officer Raja Akram said.The German bank added that it remains on track to "deliver strong operating performance" for the year, supported by sustained cost discipline and an expected year-on-year improvement in credit loss provisions amid a normalizing macroeconomic backdrop.

Jefferies Adjusts Wuxi Lead Intelligent Equipment's Price Target to 67 Yuan from 62 Yuan, Keeps at Buy